Methotrexate

Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis
Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi

Annals of the Rheumatic Diseases May 2021, annrheumdis-2021-220315; DOI: 10.1136/annrheumdis-2021-220315
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland
Aron Hjalti Bjornsson, Gerdur Grondal, Mar Kristjansson, Thorunn Jonsdottir, Thorvardur Jon Love, Bjorn Gudbjornsson

Annals of the Rheumatic Diseases May 2021, 80 (5) 671-672; DOI: 10.1136/annrheumdis-2020-219564
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2020-219825; DOI: 10.1136/annrheumdis-2020-219825
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa, Gerd R Burmester

Annals of the Rheumatic Diseases Mar 2021, 80 (3) 304-311; DOI: 10.1136/annrheumdis-2020-218510
Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study
Elise van Mulligen, Annette van der Helm-van Mil, Pascal Hendrik Pieter de Jong

Annals of the Rheumatic Diseases Jan 2021, annrheumdis-2020-219499; DOI: 10.1136/annrheumdis-2020-219499
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
Elise van Mulligen, Angelique E Weel, Tjallingius Martijn Kuijper, N H A M Denissen, Andreas H Gerards, Mike H de Jager, Wai-Kwan Lam-Tse, J M Hazes, Annette van der Helm-van Mil, Pascal Hendrik Pieter de Jong, Jolanda J Luime

Annals of the Rheumatic Diseases Dec 2020, 79 (12) 1550-1556; DOI: 10.1136/annrheumdis-2020-217528
Biologics, spondylitis and COVID-19
James Todd Rosenbaum, Hedley Hamilton, Dongseok Choi, Michael H Weisman, John D Reveille, Kevin L Winthrop

Annals of the Rheumatic Diseases Dec 2020, 79 (12) 1663-1665; DOI: 10.1136/annrheumdis-2020-217941
Response to: ‘Correspondence on ‘Tapering towards DMARD-free remission in rheumatoid arthritis’ by Garcia et al
Elise van Mulligen, Pascal Hendrik Pieter de Jong

Annals of the Rheumatic Diseases Nov 2020, annrheumdis-2020-219293; DOI: 10.1136/annrheumdis-2020-219293
Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’
Ran Cui, Qiang Tong, Zhi-Yong Chen, Miao Chen, Sheng-Ming Dai

Annals of the Rheumatic Diseases Oct 2020, annrheumdis-2020-219173; DOI: 10.1136/annrheumdis-2020-219173
Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive
Mandy Greenwood, Muhammad Shipa, Su-Ann Yeoh, Euthalia Roussou, Dev Mukerjee, Michael R Ehrenstein

Annals of the Rheumatic Diseases Nov 2020, 79 (11) 1516-1517; DOI: 10.1136/annrheumdis-2020-217725

Main menu

Methotrexate

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Methotrexate

Pages